GB9004890D0 - Leukaemia inhibitory factor - Google Patents

Leukaemia inhibitory factor

Info

Publication number
GB9004890D0
GB9004890D0 GB909004890A GB9004890A GB9004890D0 GB 9004890 D0 GB9004890 D0 GB 9004890D0 GB 909004890 A GB909004890 A GB 909004890A GB 9004890 A GB9004890 A GB 9004890A GB 9004890 D0 GB9004890 D0 GB 9004890D0
Authority
GB
United Kingdom
Prior art keywords
inhibitory factor
leukaemia inhibitory
leukaemia
factor
inhibitory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB909004890A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEATH JOHN K
Original Assignee
HEATH JOHN K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEATH JOHN K filed Critical HEATH JOHN K
Priority to GB909004890A priority Critical patent/GB9004890D0/en
Publication of GB9004890D0 publication Critical patent/GB9004890D0/en
Priority to JP3505302A priority patent/JPH05504955A/ja
Priority to PCT/GB1991/000334 priority patent/WO1991013985A1/en
Priority to EP91905515A priority patent/EP0518933A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Carbon Steel Or Casting Steel Manufacturing (AREA)
GB909004890A 1990-03-05 1990-03-05 Leukaemia inhibitory factor Pending GB9004890D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB909004890A GB9004890D0 (en) 1990-03-05 1990-03-05 Leukaemia inhibitory factor
JP3505302A JPH05504955A (ja) 1990-03-05 1991-03-05 白血病抑制因子
PCT/GB1991/000334 WO1991013985A1 (en) 1990-03-05 1991-03-05 Leukaemia inhibitory factor
EP91905515A EP0518933A1 (en) 1990-03-05 1991-03-05 Leukaemia inhibitory factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909004890A GB9004890D0 (en) 1990-03-05 1990-03-05 Leukaemia inhibitory factor

Publications (1)

Publication Number Publication Date
GB9004890D0 true GB9004890D0 (en) 1990-05-02

Family

ID=10672019

Family Applications (1)

Application Number Title Priority Date Filing Date
GB909004890A Pending GB9004890D0 (en) 1990-03-05 1990-03-05 Leukaemia inhibitory factor

Country Status (4)

Country Link
EP (1) EP0518933A1 (ja)
JP (1) JPH05504955A (ja)
GB (1) GB9004890D0 (ja)
WO (1) WO1991013985A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138268T1 (de) * 1990-03-20 1996-06-15 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
WO1993012806A1 (en) * 1991-12-24 1993-07-08 Amrad Corporation Limited A method for the treatment of tumours and sarcomas
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
US5340740A (en) * 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
WO1994003585A1 (en) * 1992-08-04 1994-02-17 Commonwealth Scientific And Industrial Research Organisation A method for maintaining embryonic stem cells and avian factor useful for same
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
WO1995020661A1 (en) * 1994-01-27 1995-08-03 Bresatec Ltd. Materials and methods for management of hyperacute rejection in human xenotransplantation
AU2012202157B2 (en) * 2005-07-19 2013-07-11 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
ES2710601T3 (es) 2005-07-19 2019-04-26 Stemgen S P A Inhibición del potencial tumorigénico de células madre tumorales por LIF
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

Also Published As

Publication number Publication date
JPH05504955A (ja) 1993-07-29
EP0518933A1 (en) 1992-12-23
WO1991013985A1 (en) 1991-09-19

Similar Documents

Publication Publication Date Title
HK33695A (en) Leukaemia inhibitory factor
DE4190756D2 (en) Mikrotom
DE69125252D1 (en) Röntgentherapie-simulatormachine
EP0440282A3 (en) Sensormatrix
DE69126781D1 (en) Fabry-perot-modulator
ZA914983B (en) His-grf-analogs
DE69116171D1 (en) Photo- und biologisch-abbaubare polyethen-copolymere
DE69127252D1 (en) Linearlager
DE4092449D2 (de) Taschenfederkernmatratze
AU111085S (en) Sunlounger
DE4191708D2 (en) Festkoerperlaser
GB9004890D0 (en) Leukaemia inhibitory factor
EP0440493A3 (en) Tape-cartridge case
EP0441276A3 (en) Electrophotoreceptor
DE4092685D2 (en) Mehrkomponenten-kleb- und -werkstoffverarbeitungssystem
GB9009497D0 (en) Case
EP0439820A3 (en) Vacuumswitch
EP0442371A3 (en) Bisglycosides
AU110900S (en) Facsimilie
DE4191594D2 (en) Sicherheitsgurtverschluss
AU109294S (en) Listello
ZA882277B (en) Leukaemia inhibitory factor
CA66054S (en) Show case
CA66527S (en) Case
CA66268S (en) Snow-bucket